GLP-1s and vision loss: Risk increase real but negligible

Two observational studies published in the Annals of Internal Medicine found that GLP-1 receptor agonists may be associated with a small increase in the risk of nonarteritic anterior ischemic optic neuropathy, a rare condition that can cause sudden vision loss. Researchers emphasized that the absolute risk remains very low, with only a few additional cases per 10,000 patients, and that the benefits of GLP-1 medications for diabetes, weight management, and cardiovascular and kidney health generally outweigh the potential risk. Experts advised patients not to stop treatment based on these findings alone but to seek urgent care for sudden vision changes and discuss individual risk factors with clinicians.

Summary generated July 31, 2026. AI summaries can make mistakes.